Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PPIH
2176
Perma-Pipe International
PPIH
$218M
| $1.7M | ﹤0.01% |
180,298
-15,133
| -8% | -$143K |
|
2177
Radcom
RDCM
$176M
| $1.7M | ﹤0.01% |
155,633
-6,200
| -4% | -$64.3K |
|
2178
DMC Global
BOOM
$155M
| $1.7M | ﹤0.01% |
87,568
+55,571
| +174% | +$1.03M |
|
2179
Actinium Pharmaceuticals
ATNM
$32.6M
| $1.7M | ﹤0.01% |
159,600
+81,300
| +104% | +$825K |
|
2180
iMGP DBi Managed Futures Strategy ETF
DBMF
$4.2B
| $1.7M | ﹤0.01% |
58,300
-58,390
| -50% | -$1.89M |
|
2181
Edgewell Personal Care
EPC
$1.31B
| $1.69M | ﹤0.01% |
+43,900
| New | +$1.74M |
|
2182
Reading International Class A
RDI
$36.6M
| $1.68M | ﹤0.01% |
607,490
-34,000
| -5% | -$109K |
|
|
ARIS
2183
DELISTED
Aris Water Solutions
ARIS
| $1.68M | ﹤0.01% |
116,600
-39,194
| -25% | -$602K |
|
2184
Vertex
VERX
$2.06B
| $1.68M | ﹤0.01% |
115,800
+7,800
| +7% | +$125K |
|
2185
Renasant Corp
RNST
$3.98B
| $1.68M | ﹤0.01% |
44,600
-36,028
| -45% | -$1.36M |
|
2186
Merchants Bancorp
MBIN
$2.52B
| $1.68M | ﹤0.01% |
68,900
-11,300
| -14% | -$275K |
|
2187
Dynatrace
DT
$14.2B
| $1.67M | ﹤0.01% |
43,700
-42,500
| -49% | -$1.54M |
|
|
PFIE
2188
DELISTED
Profire Energy, Inc
PFIE
| $1.67M | ﹤0.01% |
1,577,235
+32,740
| +2% | +$33.3K |
|
2189
Kadant
KAI
$3.95B
| $1.67M | ﹤0.01% |
9,400
-3,700
| -28% | -$658K |
|
|
GNTY
2190
DELISTED
Guaranty Bancshares
GNTY
| $1.67M | ﹤0.01% |
48,169
+2,300
| +5% | +$81.5K |
|
2191
Accel Entertainment
ACEL
$1.01B
| $1.67M | ﹤0.01% |
216,500
+3,600
| +2% | +$30.9K |
|
2192
KLX Energy Services
KLXE
$35.3M
| $1.67M | ﹤0.01% |
96,300
+62,800
| +187% | +$884K |
|
2193
Akebia Therapeutics
AKBA
$242M
| $1.67M | ﹤0.01% |
2,886,227
-130,200
| -4% | -$40.8K |
|
2194
Envela
ELA
$416M
| $1.66M | ﹤0.01% |
315,604
-5,700
| -2% | -$29.2K |
|
2195
First Trust Morningstar Dividend Leaders Index Fund
FDL
$7.99B
| $1.66M | ﹤0.01% |
+45,400
| New | +$1.64M |
|
2196
FlexShares Global Upstream Natural Resources Index Fund
GUNR
$7.04B
| $1.65M | ﹤0.01% |
38,000
-60,600
| -61% | -$2.57M |
|
|
BLU
2197
DELISTED
BELLUS Health Inc.
BLU
| $1.65M | ﹤0.01% |
+200,738
| New | +$1.87M |
|
|
CODX
2198
Co-Diagnostics
CODX
$9.77M
| $1.65M | ﹤0.01% |
21,807
-1,686
| -7% | -$158K |
|
2199
Passage Bio
PASG
$14.8M
| $1.64M | ﹤0.01% |
59,558
-3,512
| -6% | -$88.6K |
|
2200
MiMedx Group
MDXG
$622M
| $1.64M | ﹤0.01% |
590,685
+34,300
| +6% | +$103K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 522 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 522 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.